BR0312789A - Novos derivados de piperazinil - pirazinona para o tratamento de distúrbios relacionados ao receptor 5-ht2a - Google Patents
Novos derivados de piperazinil - pirazinona para o tratamento de distúrbios relacionados ao receptor 5-ht2aInfo
- Publication number
- BR0312789A BR0312789A BR0312789-3A BR0312789A BR0312789A BR 0312789 A BR0312789 A BR 0312789A BR 0312789 A BR0312789 A BR 0312789A BR 0312789 A BR0312789 A BR 0312789A
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- related disorders
- ht2a receptor
- compounds
- new
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
"NOVOS DERIVADOS DE PIPERAZINIL - PIRAZINONA PARA O TRATAMENTO DE DISTúRBIOS RELACIONADOS AO RECEPTOR 5-HT~ 2A~". A presente invenção se refere a compostos com a fórmula geral (I): em que os índices m e n e os substituintes R^ 1^, R^ 2^, R^ 3^, R^ 4^, R^ 5^ e R^ 6^ são como definidos no relatório descritivo e/ou no quadro reivindicatório do presente pedido de patente. A presente invenção adicionalmente se refere às composições farmacêuticas compreendendo os compostos de fórmula geral (I), aos processos para a sua preparação, e bem como à utilização dos compostos de fórmula geral (I) para a preparação de um medicamento para o tratamento de transtornos ou de condições médicas relacionados ao receptor 5-HT~ 2A~.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0202287A SE0202287D0 (sv) | 2002-07-19 | 2002-07-19 | New compounds |
US42624002P | 2002-11-14 | 2002-11-14 | |
PCT/SE2003/001102 WO2004009586A1 (en) | 2002-07-19 | 2003-06-25 | Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0312789A true BR0312789A (pt) | 2005-05-03 |
Family
ID=30772315
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0312789-3A BR0312789A (pt) | 2002-07-19 | 2003-06-25 | Novos derivados de piperazinil - pirazinona para o tratamento de distúrbios relacionados ao receptor 5-ht2a |
Country Status (21)
Country | Link |
---|---|
US (1) | US7244722B2 (pt) |
EP (1) | EP1534391B1 (pt) |
KR (1) | KR20050025628A (pt) |
CN (1) | CN1305871C (pt) |
AR (1) | AR040605A1 (pt) |
AT (1) | ATE353693T1 (pt) |
AU (1) | AU2003243101B2 (pt) |
BR (1) | BR0312789A (pt) |
CA (1) | CA2492924C (pt) |
DE (1) | DE60311822T2 (pt) |
DK (1) | DK1534391T3 (pt) |
ES (1) | ES2281666T3 (pt) |
HK (1) | HK1080859A1 (pt) |
IL (1) | IL166226A0 (pt) |
MX (1) | MXPA05000784A (pt) |
MY (1) | MY139613A (pt) |
NO (1) | NO20050903L (pt) |
NZ (1) | NZ537629A (pt) |
PT (1) | PT1534391E (pt) |
TW (1) | TW200404067A (pt) |
WO (1) | WO2004009586A1 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050070527A1 (en) * | 2003-09-30 | 2005-03-31 | Edwards James P. | Quinoxaline compounds |
DE102004023332A1 (de) * | 2004-05-12 | 2006-01-19 | Bayer Cropscience Gmbh | Chinoxalin-2-on-derivate, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung und deren Verwendung |
JP2009537602A (ja) * | 2006-05-22 | 2009-10-29 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 薬剤として用いるための置換ピラジノン誘導体 |
WO2008043775A1 (en) * | 2006-10-12 | 2008-04-17 | Janssen Pharmaceutica Nv | Substituted pyrazinone derivatives for use as a medicine |
RU2479580C2 (ru) | 2007-06-27 | 2013-04-20 | Астразенека Аб | Производные пиразинона и их применение для лечения легочных заболеваний |
EP2268624B1 (en) * | 2008-04-29 | 2013-07-31 | Merck Patent GmbH | Arylpyrazinone derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes |
US11306122B2 (en) * | 2019-06-14 | 2022-04-19 | The United States Government As Represented By The Department Of Veterans Affairs | Compositions and methods of inhibiting the binding of plasma IgG autoantibodies to serotonin 2A receptor |
WO2023039408A1 (en) * | 2021-09-07 | 2023-03-16 | The Trustees Of Columbia University In The City Of New York | Methods of treating chronic obstructive pulmonary disease including compounds useful therein |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI193974A (pt) * | 1973-07-13 | 1975-01-14 | Merck & Co Inc | |
SE421695B (sv) * | 1975-04-21 | 1982-01-25 | Merck & Co Inc | Sett att framstella piperazinylpyraziner |
US4163849A (en) * | 1978-03-17 | 1979-08-07 | Merck & Co., Inc. | Piperazinylpyrazines |
ATE114467T1 (de) | 1990-06-01 | 1994-12-15 | Merrell Dow Pharma | (+)-alpha-(2,3 dimethoxyphenyl)-1-(2- (fluorophenyl)ethyl>-4-piperidinmethanol. |
IT1249678B (it) | 1991-07-12 | 1995-03-09 | Ciro Costagliola | Collirio per il trattamento della ipertensione oculare |
US5538974A (en) | 1994-01-27 | 1996-07-23 | Senju Pharamceutical Co., Ltd. | Ophthalmic composition for lowering intraocular pressure |
ZA954689B (en) * | 1994-06-08 | 1996-01-29 | Lundbeck & Co As H | 4-Aryl-1-(indanmethyl dihydrobenzofuranmethyl or dihydrobenzothiophenemethyl) piperidines tetrahydropyridines or piperazines |
JP4063341B2 (ja) | 1994-07-06 | 2008-03-19 | メイ株式会社 | 緑内障治療剤及び眼圧降下剤 |
FR2765107B1 (fr) | 1997-06-26 | 2000-03-24 | Sanofi Sa | Utilisation d'un antagoniste specifique des recepteurs 5ht2 pour la preparation de medicaments utiles dans le traitement du syndrome d'apnee du sommeil |
SE9801516D0 (sv) | 1998-04-30 | 1998-04-30 | Maria Carlsson | M100907/4-Piperidinemethanol derivatives for autism |
WO2000012090A1 (en) | 1998-08-28 | 2000-03-09 | Aventis Pharmaceuticals Inc. | THE USE OF R(+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL FOR THE TREATMENT OF SLEEP DISORDERS |
KR100722090B1 (ko) * | 1999-05-21 | 2007-05-25 | 바이오비트럼 에이비 | 신규 화합물, 이의 용도 및 이의 제조 방법 |
US20020099076A1 (en) | 2000-05-25 | 2002-07-25 | Richard Scheyer D. | Use of (+)-a-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis |
-
2003
- 2003-06-25 DK DK03765414T patent/DK1534391T3/da active
- 2003-06-25 WO PCT/SE2003/001102 patent/WO2004009586A1/en active IP Right Grant
- 2003-06-25 AT AT03765414T patent/ATE353693T1/de active
- 2003-06-25 MX MXPA05000784A patent/MXPA05000784A/es active IP Right Grant
- 2003-06-25 AU AU2003243101A patent/AU2003243101B2/en not_active Ceased
- 2003-06-25 ES ES03765414T patent/ES2281666T3/es not_active Expired - Lifetime
- 2003-06-25 BR BR0312789-3A patent/BR0312789A/pt not_active IP Right Cessation
- 2003-06-25 EP EP03765414A patent/EP1534391B1/en not_active Expired - Lifetime
- 2003-06-25 NZ NZ537629A patent/NZ537629A/en not_active IP Right Cessation
- 2003-06-25 PT PT03765414T patent/PT1534391E/pt unknown
- 2003-06-25 CN CNB038195844A patent/CN1305871C/zh not_active Expired - Fee Related
- 2003-06-25 KR KR1020057001012A patent/KR20050025628A/ko not_active Application Discontinuation
- 2003-06-25 DE DE60311822T patent/DE60311822T2/de not_active Expired - Lifetime
- 2003-06-25 CA CA2492924A patent/CA2492924C/en not_active Expired - Fee Related
- 2003-07-17 TW TW092119594A patent/TW200404067A/zh unknown
- 2003-07-17 MY MYPI20032688A patent/MY139613A/en unknown
- 2003-07-17 US US10/622,055 patent/US7244722B2/en not_active Expired - Fee Related
- 2003-07-18 AR AR20030102607A patent/AR040605A1/es unknown
-
2005
- 2005-01-10 IL IL16622605A patent/IL166226A0/xx unknown
- 2005-02-18 NO NO20050903A patent/NO20050903L/no not_active Application Discontinuation
-
2006
- 2006-01-20 HK HK06100948A patent/HK1080859A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
NO20050903L (no) | 2005-04-18 |
IL166226A0 (en) | 2006-01-15 |
WO2004009586A1 (en) | 2004-01-29 |
ATE353693T1 (de) | 2007-03-15 |
ES2281666T3 (es) | 2007-10-01 |
EP1534391B1 (en) | 2007-02-14 |
KR20050025628A (ko) | 2005-03-14 |
AU2003243101B2 (en) | 2010-05-13 |
NZ537629A (en) | 2007-05-31 |
AU2003243101A1 (en) | 2004-02-09 |
PT1534391E (pt) | 2007-05-31 |
US20040063693A1 (en) | 2004-04-01 |
CA2492924C (en) | 2011-12-20 |
CA2492924A1 (en) | 2004-01-29 |
CN1305871C (zh) | 2007-03-21 |
EP1534391A1 (en) | 2005-06-01 |
DE60311822T2 (de) | 2007-12-06 |
CN1675198A (zh) | 2005-09-28 |
US7244722B2 (en) | 2007-07-17 |
HK1080859A1 (en) | 2006-05-04 |
AR040605A1 (es) | 2005-04-13 |
TW200404067A (en) | 2004-03-16 |
MY139613A (en) | 2009-10-30 |
MXPA05000784A (es) | 2005-06-17 |
DK1534391T3 (da) | 2007-06-11 |
DE60311822D1 (de) | 2007-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0214342A (pt) | Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1 | |
MY132789A (en) | Diarylcycloalkyl derivatives, process for their preparation and their use as pharmaceuticals | |
BRPI0108395B8 (pt) | derivados de pirrolopirimidinona, processos de preparação e uso | |
ATE381537T1 (de) | Formanilid-derivative als beta2-adrenorezeptor- agonisten | |
BRPI0407504A (pt) | heterociclos n-arila substituìdo, processo para sua preparação e uso dos mesmos como medicamentos | |
BR0316264A (pt) | Medicamento para tratamento de doença pulmonar obstrutiva crÈnica | |
CU23208A3 (es) | Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea | |
ES2193875A1 (es) | Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos. | |
BR0212008A (pt) | Uso de um composto ou de um sal, solvato ou pró-medicamento deste, composição farmacêutica, composto ou um sal, solvato ou pró-medicamento deste, e, processo para a preparação deste | |
BRPI0519398A2 (pt) | compostos de piridina para o tratamento de doenÇas mediadas por prostaglandina | |
TW200736189A (en) | Indene derivatives, their preparation and use as medicaments | |
BRPI0508724A (pt) | derivados do fenilaminoetanol como agonistas do receptor beta2 | |
BR0315143A (pt) | Composto, processo para a preparação dos (r) e (s) - enanciÈmeros individuais ou misturas de enanciÈmeros e sais farmaceuticamente aceitáveis de um composto, composição farmacêutica, e, uso de um composto | |
TW200616985A (en) | Salicylthiazoles substituted by diphenylamine or diphenylamine derivatives, process for their preparation and their use | |
BRPI0412997A (pt) | derivados de dióxido de tiazol-benzoisotiazol substituìdos, método para produzir os mesmos e seu uso | |
BR0214243A (pt) | Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida | |
BRPI0417833A (pt) | novos derivados de benzofurano, os quais podem ser usados na profilaxia ou tratamento de distúrbios relacionados com o receptor 5-ht6 | |
BRPI0407253A (pt) | Heterociclil-3-sulfonilindazóis como ligandos 5-hidroxitriptamina-6 processo de preparação dos mesmos, seus usos na preparação de uma composição farmacêutica e composição farmacêutica compreendendo os referidos compostos | |
BR9910179A (pt) | Composto, composição farmacêutica, uso de um composto, e, processo para tratar uma doença ou condição mediada por fator xa em um animal de sangue quente | |
EA200971086A1 (ru) | Фармацевтические композиции и способ лечения шизофрении | |
BR0312722A (pt) | Derivados de pirazol heterobicìclico como inibidores de qinase | |
MEP42908A (en) | Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use of the same as medicaments, and medicament containing such compounds | |
BR0312789A (pt) | Novos derivados de piperazinil - pirazinona para o tratamento de distúrbios relacionados ao receptor 5-ht2a | |
BR112023002082A2 (pt) | Síntese de derivados de imipridona e sua avaliação para sua atividade anticancerígena | |
BRPI0411729A (pt) | dicetopiperazinas substituìdas e seu uso como antagonistas da oxitocina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25D | Requested change of name of applicant approved |
Owner name: BIOVITRUM AB (PUBL) (SE) Free format text: ALTERADO DE: BIOVITRUM AB |
|
B15I | Others concerning applications: loss of priority |
Free format text: PERDA DA PRIORIDADE REIVINDICADA (US60/426,240) DE ACORDO COM A LEI NO 9.279 DE 14 DE MAIO DE 1996 ART.16 7O POR NAO ATENDER AO DISPOSTO NO 6O DESTE ARTIGO. |
|
B150 | Others concerning applications: publication cancelled [chapter 15.30 patent gazette] |
Free format text: ANULADA A PERDA DE PRIORIDADE(15.9) PUBLICADA NA RPI 2016 POR TER SIDO INDEVIDA. |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 10A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014. |